drugset / Trial / NCT06276933
A Study of Camrelizumab Combined With Chemotherapy ± Thalidomide in First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
Phase 4
Not yet recruiting
104 enrolled
Tongji University
Shanghai Pulmonary Hospital, Shanghai, China · collab
RandomizedSequentialQuadruple-blindTreatment
Summary
To explore and evaluate the safety and efficacy of camrelizumab combined with chemotherapy ± thalidomide in first-line treatment of advanced non-small cell lung cancer patients
Timeline
- Start
- 2024-02-22
- Primary completion
- 2025-11-22
- Completion
- 2026-11-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camrelizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Thalidomide | Other / unclassified | 100 mg | Oral |
| Background | Carboplatin | Small molecule | — | — |
| Background | Cisplatin | Other / unclassified | — | — |
| Background | Paclitaxel | Small molecule | — | — |
| Background | Pemetrexed | Small molecule | — | — |